Brazil emerges as major rare earths source for India Ivar AI

KQED

SpaceX Blasts Off With a Record-Breaking $75 Billion IPO

BusinessLine

SpaceX IPO pushes Elon Musk’s net worth past $1 trillion

The Times of India

US stocks: SpaceX to make historic listing on Nasdaq on Friday that could make Elon Musk a trillionaire

Yahoo Entertainment

美伊衝突再掀地緣風險美股跌逾1%科技股重挫

Expansion.com

La mayor ola inversora de la historia: 14 billones para 2030

GlobeNewswire

Cellectis Receives FDA RMAT Designation for lasme-cel, the First Allogeneic CAR-T Therapy in a Pivotal Trial for Patients with r/r B-ALL

Secretchina.com

马斯克逼近万亿身家 SpaceX创史上最大IPO(图)

Nacion.com

Estados Unidos vuelve a bombardear Irán en respuesta al derribo de un helicóptero

Crypto Briefing

SpaceX IPO set to generate tens of billions in returns for early backers

The Times of India

Biggest-ever IPO: Retail investors line up, bid over $70 billion for SpaceX

Crypto Briefing

S&P 500 rallies nearly 2% as reports signal potential end to Iran conflict

POLITICO.eu

US launches a second straight day of airstrikes in Iran

Abril.com.br

SpaceX estreia na Bolsa com IPO recorde de US$ 75 bilhões

Crypto Briefing

SpaceX surges on debut, making Elon Musk the world’s first trillionaire

BBC News

EUA lançam novos ataques contra o Irã após Trump ameaçar 'atingir o país com força' diante da falta de acordo

Latercera.com

SpaceX confirma precio de colocación y se convertiría en la mayor apertura bursátil de la historia

The Times of India

US stocks: Oppenheimer launches Wall Street's first coverage of SpaceX with bullish outlook

Diariobitcoin.com

Mercado de CPU para servidores crecería 5 veces hacia 2030 por auge de la IA agentiva

Crypto Briefing

Iran shuts down Strait of Hormuz after US military strikes

$Cellectis reçoit le statut RMAT de la FDA pour lasmé-cel, la première thérapie CAR-T allogénique en essai pivot pour les patients atteints de LLA-B en rechute ou réfractaire$

GlobeNewswire

Cellectis reçoit le statut RMAT de la FDA pour lasmé-cel, la première thérapie CAR-T allogénique en essai pivot pour les patients atteints de LLA-B en rechute ou réfractaire